Louise Frederika Kooij Sells 26,011 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 26,011 shares of the stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $35.68, for a total transaction of $928,072.48. Following the completion of the transaction, the chief accounting officer owned 15,000 shares in the company, valued at $535,200. This represents a 63.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Louise Frederika Kooij also recently made the following trade(s):

• On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.30, for a total transaction of $1,548,681.60.
• On Tuesday, December 23rd, Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $36.21, for a total transaction of $2,719,986.57.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ:NAMS opened at $34.74 on Wednesday. NewAmsterdam Pharma Company N.V. has a 12 month low of $14.06 and a 12 month high of $42.00. The firm has a market capitalization of $3.94 billion, a P/E ratio of -16.95 and a beta of 0.05. The company’s fifty day moving average price is $37.00 and its 200 day moving average price is $29.23.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.03). NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%.The firm had revenue of $0.35 million for the quarter, compared to analysts’ expectations of $4.54 million. On average, sell-side analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.

Analyst Ratings Changes

Several research firms have commented on NAMS. HC Wainwright started coverage on NewAmsterdam Pharma in a research report on Monday, October 20th. They set a “buy” rating and a $52.00 price target on the stock. Royal Bank Of Canada lifted their target price on shares of NewAmsterdam Pharma from $39.00 to $44.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Stifel Nicolaus upped their price target on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Citigroup raised their price objective on shares of NewAmsterdam Pharma from $42.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Wednesday, October 8th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $45.90.

Hedge Funds Weigh In On NewAmsterdam Pharma

Hedge funds and other institutional investors have recently bought and sold shares of the company. Frazier Life Sciences Management L.P. increased its stake in NewAmsterdam Pharma by 3.0% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company’s stock valued at $300,754,000 after buying an additional 490,656 shares during the period. RA Capital Management L.P. boosted its holdings in shares of NewAmsterdam Pharma by 14.6% in the first quarter. RA Capital Management L.P. now owns 10,138,938 shares of the company’s stock valued at $207,544,000 after acquiring an additional 1,293,938 shares in the last quarter. Capital World Investors boosted its holdings in shares of NewAmsterdam Pharma by 17.1% in the third quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock valued at $279,358,000 after acquiring an additional 1,434,986 shares in the last quarter. Jennison Associates LLC increased its stake in shares of NewAmsterdam Pharma by 42.5% during the third quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock worth $119,407,000 after acquiring an additional 1,252,451 shares during the period. Finally, Wellington Management Group LLP raised its holdings in NewAmsterdam Pharma by 21.0% during the third quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock worth $114,332,000 after purchasing an additional 697,129 shares in the last quarter. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.